Assessment of Endothelial Dysfunction With Flow-Mediated Dilatation in Myeloproliferative Disorders

Yildiz A., Guryildirim M., Pepeler M. S., Yazol M., ÖZHAN OKTAR S., Acar K.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.24, no.7, pp.1102-1108, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 7
  • Publication Date: 2018
  • Doi Number: 10.1177/1076029618766260
  • Journal Name: CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1102-1108
  • Keywords: flow-mediated dilatation, endothelial dysfunction, myeloproliferative disorders, risk factors, thrombosis, POLYCYTHEMIA-VERA PATIENTS, LOW-DOSE ASPIRIN, ESSENTIAL THROMBOCYTHEMIA, RISK-FACTORS, ACUTE-LEUKEMIA, CD40 LIGAND, THROMBOSIS, NEOPLASMS, COMPLICATIONS, LEUKOCYTOSIS
  • Gazi University Affiliated: Yes

Abstract

Background: Thrombosis is the most important cardiovascular complication of classical myeloproliferative disorders (MPDs). Endothelial dysfunction (ED) is known to play a major role in the mechanism of thrombophilia in MPDs.